Penumbra, Inc. (NYSE:PEN - Get Free Report) EVP Johanna Roberts sold 600 shares of the business's stock in a transaction on Monday, May 13th. The stock was sold at an average price of $207.41, for a total transaction of $124,446.00. Following the completion of the sale, the executive vice president now directly owns 63,488 shares in the company, valued at approximately $13,168,046.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Johanna Roberts also recently made the following trade(s):
- On Monday, April 1st, Johanna Roberts sold 600 shares of Penumbra stock. The stock was sold at an average price of $217.07, for a total transaction of $130,242.00.
- On Friday, March 1st, Johanna Roberts sold 600 shares of Penumbra stock. The shares were sold at an average price of $237.68, for a total value of $142,608.00.
Penumbra Stock Performance
Shares of NYSE:PEN traded down $2.05 during trading on Thursday, reaching $202.65. 95,953 shares of the stock were exchanged, compared to its average volume of 346,631. Penumbra, Inc. has a 12 month low of $180.93 and a 12 month high of $348.67. The stock has a 50-day moving average price of $217.34 and a 200-day moving average price of $232.11. The company has a current ratio of 6.12, a quick ratio of 3.51 and a debt-to-equity ratio of 0.02. The firm has a market cap of $7.85 billion, a PE ratio of 86.39, a PEG ratio of 2.08 and a beta of 0.57.
The only AI company to buy
From Porter & Company | Ad
The AI boom is just getting started.
And the real wealth has still to be made…
You must read this new presentation from Porter Stansberry.
Penumbra (NYSE:PEN - Get Free Report) last issued its quarterly earnings data on Tuesday, May 7th. The company reported $0.41 EPS for the quarter, missing analysts' consensus estimates of $0.42 by ($0.01). The firm had revenue of $278.70 million during the quarter, compared to analyst estimates of $274.94 million. Penumbra had a net margin of 8.52% and a return on equity of 7.83%. The business's quarterly revenue was up 15.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.23 earnings per share. Research analysts expect that Penumbra, Inc. will post 2.87 EPS for the current fiscal year.
Hedge Funds Weigh In On Penumbra
Institutional investors and hedge funds have recently modified their holdings of the business. Fifth Third Bancorp boosted its holdings in Penumbra by 13.9% in the 4th quarter. Fifth Third Bancorp now owns 378 shares of the company's stock valued at $95,000 after purchasing an additional 46 shares during the period. Signaturefd LLC raised its position in shares of Penumbra by 27.2% in the 4th quarter. Signaturefd LLC now owns 215 shares of the company's stock valued at $54,000 after buying an additional 46 shares in the last quarter. Silvercrest Asset Management Group LLC boosted its position in shares of Penumbra by 3.4% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 1,680 shares of the company's stock worth $375,000 after acquiring an additional 55 shares in the last quarter. Benjamin F. Edwards & Company Inc. increased its stake in Penumbra by 171.8% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 106 shares of the company's stock valued at $27,000 after acquiring an additional 67 shares during the last quarter. Finally, Treasurer of the State of North Carolina raised its position in Penumbra by 0.4% during the third quarter. Treasurer of the State of North Carolina now owns 16,394 shares of the company's stock valued at $3,966,000 after purchasing an additional 70 shares in the last quarter. 88.88% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several brokerages recently commented on PEN. Needham & Company LLC reissued a "hold" rating on shares of Penumbra in a research report on Wednesday, May 8th. Canaccord Genuity Group decreased their target price on shares of Penumbra from $284.00 to $272.00 and set a "buy" rating for the company in a research note on Wednesday, May 8th. JPMorgan Chase & Co. lowered shares of Penumbra from an "overweight" rating to a "neutral" rating and dropped their price target for the stock from $284.00 to $250.00 in a research report on Friday, February 23rd. Piper Sandler decreased their price objective on shares of Penumbra from $290.00 to $260.00 and set an "overweight" rating for the company in a research report on Wednesday, May 8th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $289.00 target price on shares of Penumbra in a report on Friday, February 23rd. Four equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $300.64.
View Our Latest Stock Report on PEN
About Penumbra
(
Get Free Report)
Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
